Testing is worth pursuing if you're experiencing new or worsening mood symptoms and have one or more risk factors for B12 deficiency
Weekly Once or Twice Or as Directed By Medical professional
Disclosures: Emilie Crouchet: Nothing to Disclose, Mayssa DACHRAOUI: Nothing to Disclose, Frank Jhling: Nothing to Disclose, Natascha Roehlen: Nothing to Disclose, Marine Oudot: Nothing to Disclose, Sarah Durand: Nothing to Disclose, Clara Ponsolles: Nothing to Disclose, Clo Gadenne: Nothing to Disclose, Laura Meiss-Heydmann: Nothing to Disclose, Julien Moehlin: Nothing to Disclose, Romain Martin: Nothing to Disclose, Nicolas Brignon: Nothing to Disclose, Fabio Del Zompo: Nothing to Disclose, Yuji Teraoka: Nothing to Disclose, Hiroshi Aikata: Nothing to Disclose, Hiromi Abe-Chayama: Nothing to Disclose, Kazuaki Chayama: Nothing to Disclose, Antonio Saviano: Nothing to Disclose, Danijela Heide: Nothing to Disclose, Emanuele Felli: Nothing to Disclose, Patrick Pessaux: Nothing to Disclose, Mathias Heikenwlder: Nothing to Disclose, Pierre Chambon: Nothing to Disclose, Catherine Schuster: Nothing to Disclose, Joachim Lupberger: Nothing to Disclose, Atish Mukherji: Nothing to Disclose, Thomas Baumert: Nothing to Disclose 445 IMMUNO-METABOLIC DRIVEN HEPATITIS B SURFACE ANTIGEN SEROCONVERSION IN MILD AND SEVERE HEPATITIS B REACTIVATION Jayesh Kumar Sevak 1 MOJAHIDUL ISLAM 1 Gayantika Verma 1 Anoushka Saxena 1 Manoj Sharma 1 Ankur Jindal 1 Varsha Shasthry 1 Syed Naqui Kazim 2 Shiv Kumar Sarin 1 Nirupma Trehanpati 1 , 1 Institute of Liver and Biliary Sciences, 2 Jamia Milia Islamia Background: HBV mediated loss of immune control is the primary cause of HBV reactivation
Phase I clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumors
Tip: Rotate injection sites, use an OTC hydrocortisone cream for irritation, or adjust injection frequency if needed
